The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease
1984
A multi-center, randomized, double-blind trial of 3806 asymptomatic middle-aged men with type II hyperlipoproteinemia assessed the benefit of lowering cholesterol in reducing coronary heart disease (CHD) risk using cholestyramine in the test group (and a placebo in a control group) for a mean 7.4 years with both groups consuming a moderate cholesterol lowering diet. The cholestyramine group had mean plasma total and low-density-lipoprotein cholesterol reductions that were 8.5% and 12.6% greater, respectively, than the placebo group, and a 19% reduction in risk for CHD death and/or nonfatal myocardial infarction. Incidences of angina and coronary by-pass surgery were reduced about 20%. The test group had a greater number of violent and accidental deaths than the placebo group, resulting in the difference between the 2 groups of deaths from all causes being nonsignificant. (wz)
显示更多 [+] 显示较少 [-]